Antibody to HSV-2 Induced Tumor Specific Antigens in Serums From Patients With Cervical Carcinoma

Antibodies to the Herpes simplex Virus Type-2-Induced Tumor-Associated Antigen AG-4 as Markers of Recurrence in Cervical Cancer

“…AG-4 and control antigen AG-H were prepared as previously described [17], Briefly, Hep-2 cells were infected with 1.0 plaque-forming units of HSV-2 (G) per cell, absorbed for 1 h at 37 °C and overlaid with maintenance medium consisting of medium 199 sup plemented with 1 % fetal calf serum (Grand Island) and re-incubated at 37 °C for 4 h. At this time, the cells were collected by scraping, washed with barbitalbuffered saline at pH 7.4, and disrupted by freezing and thawing. Cell debris was removed by centrifuga tion at 1,550 g for 30 min and the supernatant, desig nated AG-4, was used in complement fixation tests.…”

“…The quantitative microcomplement fixation test used was originally described by Wasserman and Le vine [18]; it was adapted to a reaction volume of 0.350 ml, and the assay was performed in duplicate as previously described [17]. Briefly, a mixture of anti gen or buffer (for antibody or complement controls), antibody (adjusted so that antibody control gave less than 10 % complement fixation) and complement (re constituted lyophilized guinea pig complement; BBL Division of Bioquest) was incubated at 4 °C for 18 h, and again at 37 °C for 20 min.…”

“…The reaction was considered posi tive if more than 10% of the complement was fixed. Antibody titers are expressed as the reciprocal of the highest serum dilution giving a positive response [17].…”

Cell-Mediated Immunity to Herpes Simplex Virus Types 1 and 2 Antigens in Leukoplakia and Carcinoma in Man

“…However, the nature of the viral antigen is unclear, as it was prepared by lytic infection of Vero cells with the virus. Recent evidence has suggested that a specific carcinomaassociated non-virion antigen is present in tissue culture cells after brief infection with HSV [3][4][5][6]. The antigen has also been isolated from a squamous cell carcinoma of the lip [7] and antibody to the non-virion antigen is found in sera of patients with a variety of squamous cell carcinomas but not in sera of patients with acute or chronic herpetic infections [8,5].…”

Estimation of Type‐Specific Neutralizing Antibody to Herpes Simplex Virus Type 2 in Uterine Cervical Cancer Patients by a New Absorption Method

“…Indirect evidence to support the oncogenic role played by HSV-2 in human cervical cancer is the transformation of cultured hamster and other cells (9,17,36), prevalence among patients of antibody to early antigen (4,19), presence of viral DNA fragments in cancerous tissues (12) and finally the transforming ability of a viral DNA fragment (5,13). None of this evidence, however, can rule out the possibility that malignant cells amplify the replication of HSV-2 during its subclinical reactivation from the latent form.…”